MX9805020A - Analogos de prostaglandinas de tetrahidrofurano substituido como hipotensores oculares. - Google Patents

Analogos de prostaglandinas de tetrahidrofurano substituido como hipotensores oculares.

Info

Publication number
MX9805020A
MX9805020A MX9805020A MX9805020A MX9805020A MX 9805020 A MX9805020 A MX 9805020A MX 9805020 A MX9805020 A MX 9805020A MX 9805020 A MX9805020 A MX 9805020A MX 9805020 A MX9805020 A MX 9805020A
Authority
MX
Mexico
Prior art keywords
prostaglandins
substituted tetrahydrofuran
ocular hypotensives
tetrahydrofuran analogs
analogs
Prior art date
Application number
MX9805020A
Other languages
English (en)
Inventor
Robert D Selliah
Mark R Hellberg
Peter G Klimko
Verney L Sallee
Paul W Zinke
Original Assignee
Alcon Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Lab Inc filed Critical Alcon Lab Inc
Publication of MX9805020A publication Critical patent/MX9805020A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen análogos de prostaglandinas de tetrahidrofurano substituidos, y métodos para su uso en el tratamiento del glaucoma y la hipertension ocular.
MX9805020A 1995-12-22 1998-06-19 Analogos de prostaglandinas de tetrahidrofurano substituido como hipotensores oculares. MX9805020A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US986695P 1995-12-22 1995-12-22

Publications (1)

Publication Number Publication Date
MX9805020A true MX9805020A (es) 1998-09-30

Family

ID=21740176

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9805020A MX9805020A (es) 1995-12-22 1998-06-19 Analogos de prostaglandinas de tetrahidrofurano substituido como hipotensores oculares.

Country Status (11)

Country Link
US (4) US5994397A (es)
EP (1) EP0869794B1 (es)
JP (1) JP3032302B2 (es)
AT (1) ATE273009T1 (es)
AU (1) AU714272B2 (es)
CA (1) CA2236582C (es)
DE (1) DE69633136T2 (es)
ES (1) ES2225897T3 (es)
HK (1) HK1010874A1 (es)
MX (1) MX9805020A (es)
WO (1) WO1997023223A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0948333A1 (en) * 1996-11-01 1999-10-13 Alcon Laboratories, Inc. Use of a combination of carbonic anhydrase inhibitors and prostaglandins for treating glaucoma
US6646001B2 (en) 1997-12-19 2003-11-11 Alcon Manufacturing, Ltd. Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension
US6066671A (en) 1997-12-19 2000-05-23 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides
AU1709699A (en) 1997-12-22 1999-07-12 Alcon Laboratories, Inc. 13-oxa prostaglandins for the treatment of glaucoma and ocular hypertension
US7067144B2 (en) * 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
EP1159266B1 (en) 1999-03-05 2004-11-03 Duke University C-16 unsaturated fp-selective prostaglandins analogs
US6214611B1 (en) 1999-04-12 2001-04-10 Chirotech Technology Limited Process for the preparation of prostaglandin precursors
US6894175B1 (en) * 1999-08-04 2005-05-17 The Procter & Gamble Company 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020146439A1 (en) * 2000-03-31 2002-10-10 Delong Mitchell Anthony Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins
US20020172693A1 (en) * 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
GB0012249D0 (en) * 2000-05-19 2000-07-12 Chirotech Technology Ltd Process for the preparation of 11-oxaprostaglandins
US6441196B2 (en) 2000-05-19 2002-08-27 Alcon, Inc. Processes and novel intermediates for 11-oxa prostaglandin synthesis
US20020133009A1 (en) * 2001-03-13 2002-09-19 Lambrou George N. Method for opening potassium channels
US7351404B2 (en) 2002-02-04 2008-04-01 Allergan, Inc. Method of enhancing hair growth
US9216183B2 (en) 2002-02-04 2015-12-22 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
US8758733B2 (en) 2002-02-04 2014-06-24 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
US20040225014A1 (en) * 2003-02-14 2004-11-11 Sucampo Ag Method for treating ocular hypertension and glaucoma
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
JP2012507552A (ja) 2008-10-29 2012-03-29 アエリエ・ファーマシューティカルズ・インコーポレーテッド プロスタグラジンのアミノ酸塩
US8623918B2 (en) 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8722739B2 (en) 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US20100204335A1 (en) * 2008-12-01 2010-08-12 Allergan, Inc. Kit and composition for eyelash growth
JP2012525386A (ja) 2009-05-01 2012-10-22 アエリエ・ファーマシューティカルズ・インコーポレーテッド 疾患の治療のための二重機構阻害剤
US9149484B2 (en) 2009-11-09 2015-10-06 Allergan, Inc. Compositions and methods for stimulating hair growth
SG10201805840WA (en) * 2009-11-09 2018-08-30 Allergan Inc Compositions and methods for stimulating hair growth
US8859616B2 (en) 2011-01-21 2014-10-14 Allergan, Inc. Compounds and methods for enhancing hair growth
PT3811943T (pt) 2013-03-15 2023-03-15 Aerie Pharmaceuticals Inc Composto para uso no tratamento de distúrbios oculares
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
KR102568079B1 (ko) 2016-08-31 2023-08-17 에어리 파마슈티컬즈, 인코포레이티드 안과용 조성물
MX2019011784A (es) 2017-03-31 2019-11-18 Aerie Pharmaceuticals Inc Compuestos de aril ciclopropil-amino-isoquinolinil amida.
AU2019337703B2 (en) 2018-09-14 2023-02-02 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
WO2022035499A1 (en) * 2020-08-11 2022-02-17 Ghosh Arun K Methods for making darunavir p2-ligand precursors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4088779A (en) * 1973-05-18 1978-05-09 Ciba-Geigy Corporation 9-Oxaprostaglandins
US3883659A (en) * 1973-05-18 1975-05-13 Ciba Geigy Corp 9-Oxaprostaglandin compositions
DE2436332A1 (de) * 1974-07-27 1976-02-12 Knoll Ag Substituierte tetrahydrofurane und verfahren zu deren herstellung
DE2460977A1 (de) * 1974-12-21 1976-07-01 Knoll Ag Sterisch einheitliche 11-oxaprostaglandine und verfahren zu deren herstellung
US4133948A (en) 1975-01-16 1979-01-09 Chembro Holdings (Proprietary) Limited Monosaccharides and products resulting therefrom
ZA752806B (en) * 1975-04-30 1976-12-29 Chembro Holdings Pty Ltd Novel 11-oxa-prostaglandin analogues derivatives thereof and methods for their preparation
GB1532551A (en) * 1975-01-16 1978-11-15 Chembro Holdings Pty Ltd Furo(3,4-6)furone derivatives and their preparation
DE2739277C2 (de) * 1976-09-15 1982-06-09 Pfizer Inc., 10017 New York, N.Y. Prostaglandinderivate, Verfahren zu deren Herstellung und deren Verwendung
US5574066A (en) * 1992-10-28 1996-11-12 Allergan Intraocular pressure reducing 15-acyl prostaglandins
AU687906B2 (en) * 1993-12-15 1998-03-05 Alcon Laboratories, Inc. Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
KR950032113A (ko) * 1994-03-22 1995-12-20 우에노 도시오 프로스타글란딘 에프 에스테르
SE9401087D0 (sv) * 1994-03-31 1994-03-31 Pharmacia Ab New prostaglandin derivatives for the treatment of glaucoma or ocular hypertension

Also Published As

Publication number Publication date
DE69633136T2 (de) 2005-09-01
EP0869794B1 (en) 2004-08-11
US6369102B2 (en) 2002-04-09
AU7610696A (en) 1997-07-17
WO1997023223A1 (en) 1997-07-03
EP0869794A1 (en) 1998-10-14
ATE273009T1 (de) 2004-08-15
CA2236582C (en) 2004-08-17
US6025392A (en) 2000-02-15
JP3032302B2 (ja) 2000-04-17
DE69633136D1 (de) 2004-09-16
US6197812B1 (en) 2001-03-06
CA2236582A1 (en) 1997-07-03
AU714272B2 (en) 1999-12-23
ES2225897T3 (es) 2005-03-16
HK1010874A1 (en) 1999-07-02
US20010029265A1 (en) 2001-10-11
US5994397A (en) 1999-11-30
JPH11502234A (ja) 1999-02-23

Similar Documents

Publication Publication Date Title
MX9805020A (es) Analogos de prostaglandinas de tetrahidrofurano substituido como hipotensores oculares.
MX9702349A (es) Usos de derivado de 9-deoxi prostaglandina para tratar glaucoma.
AU5355498A (en) 15-fluoro prostaglandins as ocular hypotensives
HK1048251A1 (zh) 用於治療青光眼或眼壓過高的前列腺素衍生物
HK1027748A1 (en) Use of 3-benzoyl-phenylacetic acids, esters, or amides for treatment of glcia glaucoma
CA2315829A1 (en) Angiostatic agents and compositions for controlling ocular hypertension
WO1998020880A3 (en) 11-Halo prostaglandins for the treatment of glaucoma or ocular hypertension
MY114698A (en) A process for the isolation of galanthamine
WO1998021182A3 (en) Use of cis-δ4 analogs of prostaglandins as ocular hypotensives
AU1709699A (en) 13-oxa prostaglandins for the treatment of glaucoma and ocular hypertension
MY106109A (en) 3-arylcarbonyl-1-aminoalkyl-1h-indole-containing antiglaucoma compositions
WO1998039293A3 (en) 13-thia prostaglandins for use in glaucoma therapy
AU5258698A (en) 15-ketal prostaglandins for the treatment of glaucoma or ocular hypertension
EP0667160A3 (en) Use of prostaglandin analogs for the treatment of ocular hypertension and glaucoma.
BG102064A (en) Method for increasing the retinal blood circulation
HK1024170A1 (en) Remedial composition for intraocular hypertension or glaucoma
ATE289198T1 (de) Verwendung von flunarizin zur topischen behandlung ocularem hochdruck
WO1992010473A3 (en) 2-decarboxyl-2-alkoxyalkyl prostaglandins as ocular hypotensives
HU9301364D0 (en) Homo-prostaglandines applicables for treatment of hypertension in eyes
TW340108B (en) 1,1-difluoro-1,4-dichlorobutane and process for its preparation
BG100779A (en) Derivatives of 12.13-epoxytylosin and methods for their preparation
DE69119900T2 (de) Verwendung von Prostaglandin F3alpha als okulares Hypotensivum
SE9300735L (sv) Startblock
HK1039568A1 (en) Use of ap-1 activators to treat glaucoma and ocular hypertension.
AU6829396A (en) Compositions and their uses